Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksInforma Regulatory News (INF)

Share Price Information for Informa (INF)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 815.80
Bid: 814.60
Ask: 814.80
Change: 11.40 (1.42%)
Spread: 0.20 (0.025%)
Open: 808.80
High: 817.80
Low: 806.60
Prev. Close: 804.40
INF Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Informa adds F1000 Research to Taylor & Francis

10 Jan 2020 10:30

RNS Number : 3743Z
Informa PLC
10 January 2020
 

 

Informa LEI: 5493006VM2LKUPSEDU20 

Informa PLC Press Release

10 January 2020

Informa adds F1000 Research to the Taylor & Francis Open Access Portfolio

London: Informa (LSE: INF.L), the International Exhibitions, Events, Information Services and Advanced Learning Group, today announces further investment in developing its Open Access ("OA") publishing capabilities through the addition of F1000 Research Ltd. by Taylor & Francis.

Stephen A. Carter, Group Chief Executive, Informa PLC, said:

"Under the leadership of Annie Callanan in Taylor & Francis, we are deepening our Open Access and also now our Open Research capabilities."

He added:

"F1000 Research is a leader in its field, committed to the further development of independent, high quality Open Science and Research. We are delighted to welcome Rebecca Lawrence and the team from F1000 Research, and are committed to the further technology and capability development that Open Research needs."

Vitek Tracz, Founder, F1000, said:

"F1000 Research is a pioneer of quality and independence, with a deep commitment to Open Science and Research. Taylor & Francis is a great fit culturally and its commitment to further investment and development is timely, given the likely acceleration of Open services."

F1000 Research Ltd. offers fully managed, open research publishing services directly to research funders, learned societies and institutions, including the Wellcome Trust and the Bill & Melinda Gates Foundation.

Additionally, F1000Research is the leading independent open research publishing platform for scientists and academic scholars. Its innovative platform enables the rapid publication of academic research, whilst maintaining quality and transparency, and providing authors with greater autonomy through the process.

The addition of F1000 Research complements and extends Taylor & Francis's programme of investment to expand our presence and capabilities within the increasingly important OA publishing arena. It follows the addition of leading independent OA journal publisher, Dove Medical Press, in 2017 and ongoing internal investment in developing our range of OA publications and services, with more than 300 OA journals now published across our total journal portfolio of over 2,700 titles.

No financial details of the transaction were disclosed.

Enquiries

 

Informa PLC

Stephen A. Carter, Group Chief Executive

Gareth Wright, Group Finance Director

Richard Menzies-Gow, Director of IR & Comms

 

+44 (0)20 7017 5771

+44 (0)20 7017 7096

+44 (0)20 3377 3445

Teneo Strategy

Tim Burt / Zoë Watt

 

+44 (0)20 7240 2486

Notes to Editors

Informa PLC

Informa is a leading international Exhibitions, Events, Information Services and Scholarly Publishing Group with annual revenues approaching £3 billion. It helps commercial, professional and academic communities work smarter and make better decisions faster, through specialist content and intelligence, and opportunities to connect and learn. For more information, please visit www.informa.com.

About F1000 Research Ltd.

F1000 Research Ltd. provides innovative open access publishing platforms offering rapid publication and open peer review, whilst supporting data deposition and sharing for the research community.

F1000 Research Ltd.'s own publishing platform, F1000Research, was launched in 2013 and was the first open research publishing platform combining the ability to publish rapidly with functionality to ensure transparency, robustness and reproducibility of research. F1000Research's publishing model combines the benefits of 'pre-printing' (providing rapid publication) with quality and transparency (open data support and invited open peer review) and enables publication within days of submission, followed by open invited peer review.

Building upon the growth and success of its core platform, F1000 Research Ltd. also provides fully managed, open research publishing services directly to research funders and institutions, including Wellcome, the Bill & Melinda Gates Foundation and the Health Research Board Ireland, as well as to other scholarly publishers such as Emerald Publishing. F1000 Research combines opportunities offered by technology with a passion for identifying new ways to validate and share research.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ACQGPUMCGUPUUUU
Date   Source Headline
19th Jul 20234:49 pmRNSDirector/PDMR Shareholding
19th Jul 20237:00 amRNSTransaction in Own Shares
18th Jul 20237:00 amRNSTransaction in Own Shares
17th Jul 20237:00 amRNSTransaction in Own Shares
14th Jul 20237:00 amRNSTransaction in Own Shares
13th Jul 20237:00 amRNSTransaction in Own Shares
12th Jul 20237:00 amRNSTransaction in Own Shares
11th Jul 20237:00 amRNSTransaction in Own Shares
10th Jul 20237:00 amRNSTransaction in Own Shares
7th Jul 20239:36 amRNSHolding(s) in Company
7th Jul 20239:34 amRNSHolding(s) in Company
7th Jul 20237:00 amRNSTransaction in Own Shares
6th Jul 20237:00 amRNSTransaction in Own Shares
5th Jul 20237:00 amRNSTransaction in Own Shares
4th Jul 20234:38 pmRNSHolding(s) in Company
4th Jul 20237:00 amRNSTransaction in Own Shares
3rd Jul 20235:03 pmRNSHolding(s) in Company
3rd Jul 202310:03 amRNSTotal Voting Rights
3rd Jul 20237:00 amRNSTransaction in Own Shares
30th Jun 20237:00 amRNSTransaction in Own Shares
29th Jun 20239:53 amRNSHolding(s) in Company
29th Jun 20237:00 amRNSTransaction in Own Shares
28th Jun 20237:00 amRNSTransaction in Own Shares
27th Jun 20237:00 amRNSTransaction in Own Shares
26th Jun 20237:00 amRNSTransaction in Own Shares
23rd Jun 20237:00 amRNSTransaction in Own Shares
22nd Jun 202311:15 amRNSHolding(s) in Company
22nd Jun 20237:00 amRNSTransaction in Own Shares
21st Jun 20237:00 amRNSTransaction in Own Shares
20th Jun 20232:20 pmRNSDirector/PDMR Shareholding
20th Jun 20237:00 amRNSTransaction in Own Shares
19th Jun 20238:07 amRNSHolding(s) in Company
19th Jun 20237:00 amRNSTransaction in Own Shares
16th Jun 20237:00 amRNSTransaction in Own Shares
15th Jun 20233:37 pmRNSResult of AGM
15th Jun 20237:00 amRNSAccelerating Growth
15th Jun 20237:00 amRNSTransaction in Own Shares
14th Jun 20235:19 pmRNSHolding(s) in Company
14th Jun 20237:00 amRNSTransaction in Own Shares
13th Jun 20237:00 amRNSTransaction in Own Shares
12th Jun 20233:47 pmRNSHolding(s) in Company
12th Jun 20237:00 amRNSTransaction in Own Shares
9th Jun 20235:43 pmRNSHolding(s) in Company
9th Jun 20237:00 amRNSTransaction in Own Shares
8th Jun 20235:54 pmRNSHolding(s) in Company
8th Jun 202310:18 amRNSHolding(s) in Company
8th Jun 20237:00 amRNSTransaction in Own Shares
7th Jun 20239:44 amRNSHolding(s) in Company
7th Jun 20237:00 amRNSTransaction in Own Shares
6th Jun 20237:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.